These findings highlight ORMDL2 as a predictive marker for drug resistance across diverse mechanistic classes, implicating it in cellular programs that buffer against DNA damage, ER stress, and apoptosis, central vulnerabilities in tumor therapy. Here, ORMDL2 is linked to neoplasm.